Rigel Tumbles on Phase II RA Failure; Lilly Drug Misses, Too
AstraZeneca plc's top-line results from a Phase IIb study of fostamatinib in rheumatoid arthritis (RA) showed that the drug was superior to placebo at six weeks, but it fell short of a secondary goal of noninferiority against Humira (adalimumab, Abbott), sending shares of partner Rigel Pharmaceuticals Inc., of South San Francisco, plunging by almost 35 percent.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST